Clinical Trials Logo

Filter by:
NCT ID: NCT05150977 Completed - Clinical trials for Hypersomnia, Idiopathic

Idiopathic Hypersomnia

IDAHO
Start date: December 1, 2021
Phase:
Study type: Observational

Idiopathic hypersomnia (IH) is characterized by non-restoring night-time sleep, excessive daytime sleepiness, sleep inertia, impaired cognitive functioning and autonomic symptoms. IH seems to be long lasting, once established, but little is known about long-time consequences, and research on the relationship between idiopathic hypersomnia and all-cause mortality is however sparse. IH is thus a poorly characterized disorder of hypersomnolence, and the present study aims to answer the following research questions: 1. Are there subgroups within the IH-group, that can be retrospectively characterized out of data from polysomnography, PSG and MSLT. 2. What are the relationships between IH, and possible IH subgroups, and morbidity, mortality, and sick leave, using retrospective register data? 3. What is the natural course of IH, and possible IH subgroups, assessed with questionnaires that measures daytime sleepiness, depression, and insomnia? 4. How do subjects diagnosed with IH think about their disease, cope with it, and perceive the effects of treatments, using qualitative interviews? 185 individuals assessed and diagnosed at the Sleep unit, Uppsala university hospital between 2010-01-01 and 2019-12-31 will be contacted. After collecting informed consents, PSG and MSLT data will be analysed together with register data regarding morbidity, mortality, sick leave, and pharmacotherapy.Questionnaires used at the time of the original assessment will be reviewed and, to study the natural course of the syndrome, the same questionnaires will be sent to the participants by mail.

NCT ID: NCT05150951 Completed - Healthy Clinical Trials

An Attempt at Translating Novelty-enhanced Extinction of Context Conditioning From Rodents to Humans

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

In rodents, novel exploration has been used to strengthen the consolidation of a variety of hippocampal-dependent learning tasks. To our knowledge, no attempt have been made to translate the effect of strengthening the memory of an extinction of a context conditioning memory. This study uses virtual reality for both context conditioning and novel exploration in an attempt at translating these findings from rodents to humans, thus, using novel exploration to strengthen an extinction memory. Threat responses are measured with skin conductance and startle responses. If this effect could be shown experimentally in humans, that experimental setup could become an important tool in understanding important memory processes of fear, such as reconsolidation and behavioral tagging.

NCT ID: NCT05150938 Completed - Clinical trials for Treatment of Venous Thromboembolism in Cancer Patients

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

Start date: March 18, 2022
Phase:
Study type: Observational

This is an observational study in which patient data from the past on venous thromboembolism (VTE) in patients with cancer is studied. VTE is a condition in which a patient has problems due to the formation of blood clots in the veins. Blood clots can reduce the flow of blood to vital organs such as the heart and lungs, which can lead to them becoming damaged. VTE can also be "recurrent". This means that the blood clots have returned after treatment. People who have cancer have an increased risk of developing VTE. Three main types of anticoagulation treatments ("blood thinners") have been available for patients with cancer who also have VTE - Low molecular weight heparins (LMWHs) - Vitamin K antagonists (VKAs) - Non-vitamin K antagonist oral anticoagulants (NOACs) The treatment rivaroxaban belongs to the NOACs. Compared to other treatments available to patients who have cancer and VTE, NOACs may cause fewer medical problems and can be easier for patients to take correctly. In this study, the researchers will collect data about: - the type of VTE treatments given and for how long the treatments are taken - the risk of blood clots returning in the veins after treatment, any events of major bleeding, and the number of deaths in patients with cancer who do not have a high risk of bleeding The researchers will compare this information in the patients - who received rivaroxaban to the patients who received LMWHs - who received NOACs to the patients who received LMWHs. There will be no required visits with a study doctor or required tests in this study. The researchers will look at the health information from adult patients in Sweden who were diagnosed with cancer between 2013 and 2019 and also have VTE. The researchers will collect this information from Swedish health registers including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

NCT ID: NCT05150704 Recruiting - Myocarditis Acute Clinical Trials

MYTHS - MYocarditis THerapy With Steroids

MYTHS
Start date: October 7, 2021
Phase: Phase 3
Study type: Interventional

This is a phase III, multi-center international, single blind randomized controlled trial to test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on top of maximal support in patients with Acute myocarditis (AM).

NCT ID: NCT05149950 Recruiting - Obesity Clinical Trials

Internet Treatment for Patients With Obesity

ROLobes
Start date: January 3, 2022
Phase: N/A
Study type: Interventional

There is a strong link between obesity and reduced quality of life as well as serious sequelae of diseases. Step by step is a treatment model that has been developed at the Obesity Unit, Orebro County Region and includes six group meetings over 6-8 months. The aim is to increase patients' knowledge about the disease obesity, to provide support for lifestyle changes and weight control, and to reduce stigma-related psychosocial disorders. A 1-year pilot study aimed at evaluating the Internet-based Step by Step treatment has recently been completed. Results after 6 months of treatment show that the participants who completed the treatment were mainly satisfied with the program and the content. However, the dropouts from the treatment were more than expected.

NCT ID: NCT05149755 Recruiting - Clinical trials for Moderate Aortic Valve Stenosis

Evolutâ„¢ EXPAND TAVR II Pivotal Trial

Start date: April 27, 2022
Phase: N/A
Study type: Interventional

Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.

NCT ID: NCT05149560 Recruiting - Clinical trials for Acute Myocardial Infarction

Ticagrelor Monotherapy After Stenting

TIMO
Start date: December 4, 2021
Phase: Phase 2
Study type: Interventional

A pilot study planned to evaluate initial safety of ticagrelor monotherapy after coronary stenting due to acute myocardial infarction. The study is a single-centre, single-arm, prospective phase II study 200 patients who undergo coronary artery stenting due to NSTEMI or STEMI will be included. Primary endpoint (variable): The composite of cardiac death, spontaneous myocardial infarction or definite or probable stent thrombosis within 3 months.

NCT ID: NCT05148884 Completed - Clinical trials for Medication-Induced Dyskinesia

Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia

Start date: November 9, 2021
Phase: Phase 2
Study type: Interventional

This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.

NCT ID: NCT05147948 Recruiting - Chronic Pain Clinical Trials

iACT for PTSD and Chronic Pain

Start date: October 18, 2021
Phase: N/A
Study type: Interventional

The primary aim of this study is to investigate the effect of Internet-delivered Acceptance and commitment therapy for PTSD and comorbid chronic pain using a randomized controlled trial with waitlist control.

NCT ID: NCT05146102 Recruiting - Ethics Support Clinical Trials

Ethics Communication in Groups Among Healthcare Professionals (The Ethics-com Study).

Ethics-com
Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Moral distress has been described as a condition with frustration, guilt, anger and as one reason for health care professionals to leave the profession. Ethics communication in groups has been showed to work as support for health care professionals in ethically difficult situations and further work as a tool to improve the ethical climate and prevent moral distress. Our research group has developed the "one to five-step method" for interprofessional ethical communication in groups. The overall aim of this project: is to implement and evaluate a method for organized interprofessional communication about ethical issues in healthcare.